Short vs longer hormone therapy after salvage prostate radiation
Part of Cancer, Kidney & urinary clinical trials.
This trial compares two lengths of hormone treatment (androgen deprivation therapy) given around “salvage” radiation after prostate surgery for rising PSA. It aims to see which schedule works best to control prostate cancer while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had prostate cancer surgery (radical prostatectomy) and can join even if no lymph nodes were removed
- Your PSA has risen after surgery (biochemical recurrence), meeting the trial’s specific PSA level rules
- You are considered intermediate- or high-risk based on features like Gleason score, tumor stage, margins, and timing of PSA rise
- Your testosterone is above 150 ng/dL at the time of joining
- You have not had pelvic radiation before, and you are not able to take radiation or are not already on hormone therapy or PSA-altering medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two schedules of hormone treatment (ADT) along with salvage radiation after prostate cancer surgery, to see which one controls cancer better over the long term. It may help people who have a rising PSA level after surgery but no spread found yet.
This trial tests how well salvage radiation therapy works for prostate cancer that has come back after surgery. It looks at whether adding hormone therapy based on PSA response improves outcomes.
This trial compares two ways of giving hormone therapy (apalutamide) along with radiation after prostate removal surgery. It aims to see which approach helps maintain quality of life while controlling cancer.
This trial compares two different radiation schedules to treat prostate cancer that returned based on rising PSA blood tests after prostatectomy (prostate removal). If you qualify, it may help you and your team choose a radiation approach with the goal of controlling PSA relapse.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This trial tests whether adding hormone therapy (ADT) to stereotactic body radiation therapy (SBRT) works better than SBRT alone for men with a specific type of prostate cancer called 'unfavorable intermediate risk.' The goal is to see if the combination helps control the cancer better.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.